Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
Group Sign-on Letter to Congress Requesting FY 2019 Appropriations for the National Institute of Child Health and Human Development (NICHD)
-
Group Sign-on Letter to Congress (Senate) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program
-
Group Sign-on Letter to Congress (House) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs